{"id":979066,"date":"2026-07-07T10:00:24","date_gmt":"2026-07-07T14:00:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/"},"modified":"2026-07-07T10:00:24","modified_gmt":"2026-07-07T14:00:24","slug":"alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/","title":{"rendered":"Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy"},"content":{"rendered":"
\n

\n \u2013 Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol \u2014<\/em>\n <\/p>\n

\n \u2013 FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA \u2013<\/em>\n <\/p>\n

\n \u2013 Pivotal Phase 3 trial activities on track to initiate by year-end 2026 \u2013<\/em>\n <\/p>\n

MELBOURNE, Australia and SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics<\/a> (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received the official meeting minutes from its End-of Phase-2 (EOP2) meeting for ATH434 in Multiple System Atrophy (MSA) from the U.S. Food and Drug Administration (FDA). The minutes confirm the key elements of the registrational Phase 3 program previously announced on 9 June 2026 and the path toward a potential New Drug Application (NDA) filing.<\/p>\n

\u201cThe official meeting minutes confirm the alignment we reached with the FDA and provide a well-defined clinical development strategy for registration,\u201d said David Stamler, M.D., Chief Executive Officer. \u201cThe FDA\u2019s willingness to accept a single pivotal trial supported by confirmatory evidence reflects a clear pathway for ATH434 in MSA. With the Phase 3 design elements confirmed, we are finalizing the protocol and remain on track to initiate Phase 3 trial activities by year-end 2026.\u201d<\/p>\n

Dr. Daniel Claassen, MD, Chief Medical Advisor, commented: \u201cThe Phase 2 results for ATH434 were among the most encouraging I have seen in the field, and the alignment reached with the FDA on the Phase 3 trial design is an important next step in bringing a meaningful new treatment option to people living with this devastating disease.\u201d<\/p>\n

The EOP2 minutes confirmed that the FDA agreed with the proposed Phase 3 trial design, including the study population, treatment regimen, and efficacy endpoints. Alignment was reached on the selection and analysis of the primary endpoint \u2012 the 11-item UMSARS Part I1<\/sup> rating scale, a functional measure of activities of daily living affected in MSA. Agreement was also reached on selection of key secondary endpoints, including the Swallowing Disturbance Questionnaire (SDQ), the Orthostatic Hypotension Symptom Assessment (OHSA), and the Clinical Global Impression of Severity (CGI-S). The Phase 3 study is expected to enroll approximately 200 patients who will be randomized in a 1:1 ratio and treated with ATH434 50 mg or matching placebo twice daily for 12 months.<\/p>\n

The FDA further indicated that a single pivotal trial plus confirmatory evidence could provide the necessary data to support an approval of ATH434 for the treatment of MSA. Alterity expects that the data from its ATH434-201 Phase 2 clinical trial will provide the required confirmatory evidence. The FDA also indicated that the anticipated size of Alterity\u2019s safety database at the conclusion for the Phase 3 was reasonable. A single pivotal trial provides an efficient route to completion of the clinical development program and potential filing of an NDA, both in time and resources required. The Company also plans to offer an open label extension to participants who complete the Phase 3 trial to continue their treatment and enhance the safety database for ATH434.<\/p>\n

\n About ATH434<\/strong>\n <\/p>\n

Alterity\u2019s lead candidate, ATH434, is an oral agent designed to reduce iron accumulation and inhibit abnormal protein aggregation associated with neurodegeneration. ATH434 has been shown to reduce \u03b1-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain in preclinical models. As an iron chaperone, it has excellent potential to treat Parkinson\u2019s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). Positive results from the randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with MSA demonstrated robust clinical efficacy, target engagement as indicated by key biomarkers, and a favorable safety profile. Positive data from a second Phase 2 open-label biomarker trial in patients with more advanced MSA reinforced these results. ATH434 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and Orphan Drug Designation by the FDA and the European Commission for the treatment of MSA.<\/p>\n

\n About Multiple System Atrophy<\/strong>\n <\/p>\n

Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease that causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and\/or rigidity, autonomic dysfunction affecting involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and\/or coordination that predispose patients to falls. A pathological hallmark of MSA is the accumulation of abnormal clumping of the protein \u03b1-synuclein within oligodendrocytes, the myelin-producing support cells of the central nervous system, along with progressive neuronal loss in multiple brain regions. MSA affects up to 50,000 individuals in the U.S., and while some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no cure.2<\/sup><\/p>\n

\n About Alterity Therapeutics Limited <\/strong>\n <\/p>\n

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company\u2019s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company\u2019s website at https:\/\/alteritytx.com<\/a>.<\/p>\n

\n References<\/strong>
\n
\n 1 <\/sup>11-item UMSARS Part I (previously described as modified UMSARS I): Unified Multiple System Atrophy Rating Scale, 11-Items include: Orthostatic symptoms, Swallowing, Speech, Handwriting, Cutting food, Dressing, Hygiene, Walking, Falling, Urinary and Bowel function.
2 <\/sup>Multiple System Atrophy | National Institute of Neurological Disorders and Stroke (nih.gov)<\/a><\/p>\n

\n Authorization & Additional information<\/strong>
\n
This announcement was authorized by the Board of Directors of Alterity Therapeutics Limited.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Investors<\/strong>
\n
Elyse Shapiro
ir@alteritytx.com<\/a><\/p>\n

Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com<\/a>
+1 (415) 203-6386<\/p>\n

\n Media<\/strong>
\n
Melissa Tempra
NWR Communications
melissa@nwrcommunications.com.au<\/a><\/p>\n

Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com<\/a>
+1 (646) 577-8520<\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

\n This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section<\/em>
\n 21E<\/em>
\n of<\/em>
\n the<\/em>
\n Securities<\/em>
\n Exchange<\/em>
\n Act<\/em>
\n of<\/em>
\n 1934.<\/em>
\n The<\/em>
\n Company<\/em>
\n has<\/em>
\n tried<\/em>
\n to<\/em>
\n identify<\/em>
\n such<\/em>
\n forward-looking<\/em>
\n statements<\/em>
\n by<\/em>
\n use of such words as “expects,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such<\/em>
\n statements.<\/em>\n <\/p>\n

\n Important<\/em>
\n factors<\/em>
\n that<\/em>
\n could<\/em>
\n cause<\/em>
\n actual<\/em>
\n results<\/em>
\n to<\/em>
\n differ<\/em>
\n materially<\/em>
\n from<\/em>
\n those<\/em>
\n indicated<\/em>
\n by<\/em>
\n such<\/em>
\n forward-looking<\/em>
\n statements are<\/em>
\n described<\/em>
\n in<\/em>
\n the<\/em>
\n sections<\/em>
\n titled<\/em>
\n \u201cRisk<\/em>
\n Factors\u201d<\/em>
\n in<\/em>
\n the<\/em>
\n Company\u2019s<\/em>
\n filings<\/em>
\n with<\/em>
\n the<\/em>
\n SEC,<\/em>
\n including<\/em>
\n its<\/em>
\n most<\/em>
\n recent<\/em>
\n Annual<\/em>
\n Report on<\/em>
\n Form<\/em>
\n 20-F<\/em>
\n as<\/em>
\n well<\/em>
\n as<\/em>
\n reports<\/em>
\n on<\/em>
\n Form<\/em>
\n 6-K,<\/em>
\n including,<\/em>
\n but<\/em>
\n not<\/em>
\n limited<\/em>
\n to<\/em>
\n the<\/em>
\n following:<\/em>
\n statements<\/em>
\n relating<\/em>
\n to<\/em>
\n the<\/em>
\n Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s<\/em>
\n drug<\/em>
\n development<\/em>
\n program,<\/em>
\n including,<\/em>
\n but<\/em>
\n not<\/em>
\n limited<\/em>
\n to,<\/em>
\n ATH434,<\/em>
\n and<\/em>
\n any<\/em>
\n other<\/em>
\n statements<\/em>
\n that<\/em>
\n are<\/em>
\n not<\/em>
\n historical facts.<\/em>
\n Such<\/em>
\n statements<\/em>
\n involve<\/em>
\n risks<\/em>
\n and<\/em>
\n uncertainties,<\/em>
\n including,<\/em>
\n but<\/em>
\n not<\/em>
\n limited<\/em>
\n to,<\/em>
\n those<\/em>
\n risks<\/em>
\n and<\/em>
\n uncertainties<\/em>
\n relating<\/em>
\n to<\/em>
\n the difficulties<\/em>
\n or<\/em>
\n delays<\/em>
\n in<\/em>
\n financing,<\/em>
\n development,<\/em>
\n testing,<\/em>
\n regulatory<\/em>
\n approval,<\/em>
\n production<\/em>
\n and<\/em>
\n marketing<\/em>
\n of<\/em>
\n the<\/em>
\n Company\u2019s<\/em>
\n drug components,<\/em>
\n including,<\/em>
\n but<\/em>
\n not<\/em>
\n limited<\/em>
\n to,<\/em>
\n ATH434,<\/em>
\n the<\/em>
\n ability<\/em>
\n of<\/em>
\n the<\/em>
\n Company<\/em>
\n to<\/em>
\n procure<\/em>
\n additional<\/em>
\n future<\/em>
\n sources<\/em>
\n of<\/em>
\n financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited<\/em>
\n to,<\/em>
\n ATH434,<\/em>
\n that<\/em>
\n could<\/em>
\n slow<\/em>
\n or prevent products<\/em>
\n coming<\/em>
\n to<\/em>
\n market,<\/em>
\n the uncertainty<\/em>
\n of obtaining patent protection<\/em>
\n for<\/em>
\n the<\/em>
\n Company’s intellectual<\/em>
\n property<\/em>
\n or<\/em>
\n trade<\/em>
\n secrets, the uncertainty of successfully enforcing the Company\u2019s patent rights and the uncertainty of the Company freedom to operate.<\/em>\n <\/p>\n

\n Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks<\/em>
\n only<\/em>
\n as<\/em>
\n of<\/em>
\n the<\/em>
\n date<\/em>
\n on<\/em>
\n which<\/em>
\n it<\/em>
\n is<\/em>
\n made.<\/em>
\n We<\/em>
\n undertake<\/em>
\n no<\/em>
\n obligation<\/em>
\n to<\/em>
\n publicly<\/em>
\n update<\/em>
\n any<\/em>
\n forward-looking<\/em>
\n statement, whether<\/em>
\n written<\/em>
\n or<\/em>
\n oral,<\/em>
\n that<\/em>
\n may<\/em>
\n be<\/em>
\n made<\/em>
\n from<\/em>
\n time<\/em>
\n to<\/em>
\n time,<\/em>
\n whether<\/em>
\n as<\/em>
\n a<\/em>
\n result<\/em>
\n of<\/em>
\n new<\/em>
\n information,<\/em>
\n future<\/em>
\n developments<\/em>
\n or otherwise.<\/em>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol \u2014 \u2013 FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA \u2013 \u2013 Pivotal Phase 3 trial activities on track to initiate by year-end 2026 \u2013 MELBOURNE, Australia and SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received the official meeting minutes from its End-of Phase-2 (EOP2) meeting for ATH434 in Multiple System Atrophy (MSA) from the … <\/p>\n

Continue reading “Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-979066","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAlterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol \u2014 \u2013 FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA \u2013 \u2013 Pivotal Phase 3 trial activities on track to initiate by year-end 2026 \u2013 MELBOURNE, Australia and SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received the official meeting minutes from its End-of Phase-2 (EOP2) meeting for ATH434 in Multiple System Atrophy (MSA) from the … Continue reading "Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T14:00:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Nzg5NSM3NjkzNzY4IzIyNTY3MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy\",\"datePublished\":\"2026-07-07T14:00:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/\"},\"wordCount\":1428,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Nzg5NSM3NjkzNzY4IzIyNTY3MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/\",\"name\":\"Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Nzg5NSM3NjkzNzY4IzIyNTY3MTM=\",\"datePublished\":\"2026-07-07T14:00:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Nzg5NSM3NjkzNzY4IzIyNTY3MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Nzg5NSM3NjkzNzY4IzIyNTY3MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/","og_locale":"en_US","og_type":"article","og_title":"Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy - Market Newsdesk","og_description":"\u2013 Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol \u2014 \u2013 FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA \u2013 \u2013 Pivotal Phase 3 trial activities on track to initiate by year-end 2026 \u2013 MELBOURNE, Australia and SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received the official meeting minutes from its End-of Phase-2 (EOP2) meeting for ATH434 in Multiple System Atrophy (MSA) from the … Continue reading \"Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-07T14:00:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Nzg5NSM3NjkzNzY4IzIyNTY3MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy","datePublished":"2026-07-07T14:00:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/"},"wordCount":1428,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Nzg5NSM3NjkzNzY4IzIyNTY3MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/","name":"Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Nzg5NSM3NjkzNzY4IzIyNTY3MTM=","datePublished":"2026-07-07T14:00:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Nzg5NSM3NjkzNzY4IzIyNTY3MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Nzg5NSM3NjkzNzY4IzIyNTY3MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/979066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=979066"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/979066\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=979066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=979066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=979066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}